<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199212</url>
  </required_header>
  <id_info>
    <org_study_id>Herceptin-proteasome inhibitor</org_study_id>
    <nct_id>NCT00199212</nct_id>
  </id_info>
  <brief_title>PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2</brief_title>
  <official_title>A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the feasibility of the combination of the&#xD;
      proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to&#xD;
      determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and&#xD;
      3-weekly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 study to determine the feasibility of the combination of the proteasome inhibitor&#xD;
      bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) given either weekly or 3-weekly.&#xD;
&#xD;
      Additionally, hints about efficacy of the combination will be looked upon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and maximum tolerated dose</measure>
    <time_frame>before recurrence</time_frame>
    <description>Combination of Velcade and Herceptine in breast metastatic patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of recurrence</measure>
    <time_frame>time of recurrence</time_frame>
    <description>safety and tolerability of combinaison before recurrence of metastatic breast cance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>time before response rate</time_frame>
    <description>Tolerability and safety of combination of velcade and Herceptine</description>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Carcinoma Breast Stage IV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of trastuzumab and PS-341</intervention_name>
    <description>Trastuzumab and velcade are used according standard procedure</description>
    <other_name>PS-341, velcade</other_name>
    <other_name>trastuzumab, herceptine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female gender&#xD;
&#xD;
          2. Age &gt;= 18 years&#xD;
&#xD;
          3. ECOG performance status &lt; 2&#xD;
&#xD;
          4. Histologically proven diagnosis of breast cancer&#xD;
&#xD;
          5. Locally advanced and/or metastatic disease&#xD;
&#xD;
          6. Life expectancy of three months or longer&#xD;
&#xD;
          7. No concurrent second malignancy (except for adequately treated basal cell carcinoma of&#xD;
             the skin, in situ carcinoma of the cervix or contralateral breast cancer). Any prior&#xD;
             second malignancy must be in remission for &gt;= 5 years (except for contralateral breast&#xD;
             cancer).&#xD;
&#xD;
          8. No other serious illness or medical condition including:&#xD;
&#xD;
               -  History of documented congestive heart failure; angina pectoris requiring&#xD;
                  antianginal medication; evidence of recent (&lt; 6 months) transmural infarction on&#xD;
                  electrocardiogram (ECG); poorly controlled hypertension (e.g. systolic &gt; 180 mmHg&#xD;
                  or diastolic greater than 100 mmHg); clinically significant valvular heart&#xD;
                  disease; or high-risk uncontrolled arrhythmias.&#xD;
&#xD;
               -  Chronic lung disease&#xD;
&#xD;
               -  History of significant neurological or psychiatric disorders that would prohibit&#xD;
                  the understanding and giving of informed consent, including psychotic disorders,&#xD;
                  mental retardation, and dementia.&#xD;
&#xD;
               -  Active concurrent infection&#xD;
&#xD;
          9. No symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
         10. No rapidly progressive visceral metastases requiring immediate chemotherapy&#xD;
&#xD;
         11. No concurrent anti-cancer treatment is allowed.&#xD;
&#xD;
         12. Prior investigational biological agents are allowed, with the exception of anti-HER-2&#xD;
             therapy for any reason.&#xD;
&#xD;
         13. Previous hormonal therapy is allowed, as adjuvant and/or for metastatic breast cancer&#xD;
             (MBC).&#xD;
&#xD;
         14. Adjuvant and MBC chemotherapy allowed, provided that a minimum of 4 weeks interval has&#xD;
             elapsed between last chemotherapy administration and first study drug dose. All&#xD;
             patients who, in the opinion of the investigator, could benefit from single agent&#xD;
             Herceptin® and are not considered suitable for treatment with chemotherapy plus&#xD;
             Herceptin® can be considered for this protocol.&#xD;
&#xD;
         15. A maximum cumulative dose of previous doxorubicin &lt; 360 mg/m2 or a maximum cumulative&#xD;
             dose of epirubicin &lt; 720 mg/m2&#xD;
&#xD;
         16. Concomitant use of bisphosphonates is allowed, however if bisphosphonates are started&#xD;
             during the trial for worsening bone pain, patients should be assessed for possible&#xD;
             progressive disease.&#xD;
&#xD;
         17. Adequate organ function as defined by:&#xD;
&#xD;
               -  Neutrophils &gt;= 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
               -  Bilirubin &lt;= 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Transaminases &lt;= 2.5 x ULN or &lt;= 5 x ULN if liver metastasis&#xD;
&#xD;
               -  Creatinine &lt;= 1.5 x ULN&#xD;
&#xD;
         18. Overexpression of HER-2 in the invasive component of the primary tumor, according to&#xD;
             one of the following definitions:&#xD;
&#xD;
               -  3+ overexpression by immunohistochemistry (IHC) or&#xD;
&#xD;
               -  2+ overexpression by IHC and fluorescence in situ hybridization (FISH) test&#xD;
                  demonstrating c-erbB2 gene amplification (ratio of c-erbB2 gene signals to&#xD;
                  centromere 17 signals &gt; 2)&#xD;
&#xD;
         19. Baseline left ventricular ejection fraction (LVEF) &gt; 50% measured by multiple gated&#xD;
             acquisition scan (MUGA) or echocardiography&#xD;
&#xD;
         20. Evaluable or uni-dimensionally measurable disease according to the Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
         21. Women of childbearing potential must have a negative serum or urine pregnancy test and&#xD;
             be willing to use acceptable methods of birth control.&#xD;
&#xD;
         22. Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
&#xD;
         23. Before patient registration/randomization, informed consent must be given according to&#xD;
             International Conference of Harmonization/European Union Good Clinical Practice&#xD;
             (ICH/EU GCP), and national/local regulations.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatima Cardoso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Fatima Cardoso</name_title>
    <organization>Institut Jules Bordet</organization>
  </responsible_party>
  <keyword>HER-2 positive</keyword>
  <keyword>metastatic breast cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

